Literature DB >> 17409193

Apoptotic mechanisms in mutant LRRK2-mediated cell death.

Ciro Iaccarino1, Claudia Crosio, Carmine Vitale, Giovanna Sanna, Maria Teresa Carrì, Paolo Barone.   

Abstract

Mutations in the gene coding for leucine-rich repeat kinase 2 (LRRK2) cause autosomal-dominant Parkinson's disease. The pathological mutations have been associated with an increase of LRRK2 kinase activity, although its physiological substrates have not been identified yet. The data we report here demonstrate that disease-associated mutant LRRK2 cell toxicity is due to mitochondria-dependent apoptosis. Transient transfection of mutant LRRK2 leads to neuronal death with clear apoptotic signs. Soluble caspase inhibitors or the genetic ablation of Apaf1 protects cells from apoptotic death. Moreover, we explored the function of two protein domains in LRRK2 (LRR and WD40) and demonstrate that the lack of these protein domains has a protective effect on mitochondria dysfunctions induced by mutant LRRK2.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17409193     DOI: 10.1093/hmg/ddm080

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  85 in total

1.  LRRK2 is involved in the IFN-gamma response and host response to pathogens.

Authors:  Agnès Gardet; Yair Benita; Chun Li; Bruce E Sands; Isabel Ballester; Christine Stevens; Joshua R Korzenik; John D Rioux; Mark J Daly; Ramnik J Xavier; Daniel K Podolsky
Journal:  J Immunol       Date:  2010-10-04       Impact factor: 5.422

2.  Multiple regulatory mechanisms for the Dictyostelium Roco protein GbpC.

Authors:  Arjan Kortholt; Wouter N van Egmond; Katarzyna Plak; Leonard Bosgraaf; Ineke Keizer-Gunnink; Peter J M van Haastert
Journal:  J Biol Chem       Date:  2011-11-26       Impact factor: 5.157

3.  (G2019S) LRRK2 activates MKK4-JNK pathway and causes degeneration of SN dopaminergic neurons in a transgenic mouse model of PD.

Authors:  C-Y Chen; Y-H Weng; K-Y Chien; K-J Lin; T-H Yeh; Y-P Cheng; C-S Lu; H-L Wang
Journal:  Cell Death Differ       Date:  2012-04-27       Impact factor: 15.828

Review 4.  Mitochondria, calcium and cell death: a deadly triad in neurodegeneration.

Authors:  Fulvio Celsi; Paola Pizzo; Marisa Brini; Sara Leo; Carmen Fotino; Paolo Pinton; Rosario Rizzuto
Journal:  Biochim Biophys Acta       Date:  2009-03-04

5.  Expression of leucine-rich repeat kinase 2 (LRRK2) inhibits the processing of uMtCK to induce cell death in a cell culture model system.

Authors:  Jie Cui; Mei Yu; Jingwen Niu; Zhenyu Yue; Zhiheng Xu
Journal:  Biosci Rep       Date:  2011-10       Impact factor: 3.840

6.  The Parkinson disease protein leucine-rich repeat kinase 2 transduces death signals via Fas-associated protein with death domain and caspase-8 in a cellular model of neurodegeneration.

Authors:  Cherry Cheng-Ying Ho; Hardy J Rideout; Elena Ribe; Carol M Troy; William T Dauer
Journal:  J Neurosci       Date:  2009-01-28       Impact factor: 6.167

Review 7.  Pathways to neurodegeneration: mechanistic insights from GWAS in Alzheimer's disease, Parkinson's disease, and related disorders.

Authors:  Vijay K Ramanan; Andrew J Saykin
Journal:  Am J Neurodegener Dis       Date:  2013-09-18

8.  Unexpected lack of hypersensitivity in LRRK2 knock-out mice to MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine).

Authors:  Eva Andres-Mateos; Rebeca Mejias; Masayuki Sasaki; Xiaojie Li; Brian M Lin; Saskia Biskup; Li Zhang; Rebecca Banerjee; Bobby Thomas; Lichuan Yang; Guosheng Liu; M Flint Beal; David L Huso; Ted M Dawson; Valina L Dawson
Journal:  J Neurosci       Date:  2009-12-16       Impact factor: 6.167

Review 9.  Programmed cell death in Parkinson's disease.

Authors:  Katerina Venderova; David S Park
Journal:  Cold Spring Harb Perspect Med       Date:  2012-08-01       Impact factor: 6.915

10.  The WD40 domain is required for LRRK2 neurotoxicity.

Authors:  Nathan D Jorgensen; Yong Peng; Cherry C-Y Ho; Hardy J Rideout; Donald Petrey; Peng Liu; William T Dauer
Journal:  PLoS One       Date:  2009-12-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.